Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question

Pages: 6 Published: February 01, 2012 Report Code: GDHC0060VPT

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    Text to Speech

GlobalData, the industry analysis specialist, has released its new viewpoint, “Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question”. The report is an essential source of information for the analysis of scope of approval for Xgeva’s extended indication for patients with CRPC who are at high risk of developing bone metastases. However, the unsatisfactory results, combined with significant safety issues have cast doubt on whether Amgen will receive approval for Xgeva’s additional indication.


"The viewpoint provides information on the key drivers and challenges of the Prostate cancer market. Its scope includes:

Treatment options available for Bone Metastasis

Xgeva Could Become an Expanded Indication for CRPC patients

Final Call on 26th April 2012: $1 billion sales potential of Amgen at stake"

Reasons to Buy

The report will enhance your decision-making capability. It will allow you to understand the scope of success of Xgeva that would give a competitive edge to the company and increase its market share in the oncology segment.

Table of Contents

1 Table of Contents

1.1 List of tables

1.2 List of Figures

2 Summary

3 Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question 1

3.1 Introduction

3.2 Conclusion

4 Appendix

4.1 Methodology

4.1.1 Coverage

4.1.2 Secondary Research

4.1.3 Primary Research

4.1.4 Expert Panel Validation

4.2 Contact Us

4.3 Disclaimer

List of Tables

Table 1: Selected Phase III Clinical Trials in Castration-Resistant Prostate Cancer Patients

List of Figures

Figure 1: Denosumab Approval Timelines


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.